Executive Leadership

Partnership: It’s what turns services into solutions

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings, CEO, Frontage Laboratories
Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings, CEO, Frontage Laboratories

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

 

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Zhihe (Zeke) Li, M.D., Ph.D.

Zhihe (Zeke) Li, M.D., Ph.D.

Senior Vice President, Frontage Laboratories, Executive Director of the Board
Zhihe (Zeke) Li, M.D., Ph.D.

Zhihe (Zeke) Li, M.D., Ph.D.

Senior Vice President, Frontage Laboratories, Executive Director of the Board

Dr. Zhihe (Zeke) Li is responsible for global project management functions and the company’s corporate strategy. As one of the founders and board members of Frontage, Dr. Li has more than 20 years of related experience that began with post-doctoral training at the National Institutes of Health. Prior to Frontage, he served as Group Leader, Preclinical and Pharmacology for Scios Inc., a Johnson and Johnson company. In recent years, Dr. Li has interacted extensively with Chinese biopharmaceutical companies on novel and generic development projects. With in-depth experience in research and development of small molecules, peptides and protein drugs, he has authored and co-authored more than 40 scientific papers and patents.

Dr. Li received his medical degree and a master’s degree in pathology from Norman Bethune University of Medical Sciences in China. He earned a doctor of philosophy degree in pathology from McGill University.

linkedin logo 150x150 - Zhihe (Zeke) Li, M.D., Ph.D.

Read Full Bio
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations

Before joining Frontage, Dr Qi served as Vice President of R&D, RA and Medical and President of research institute for Hebei Changshan Biochemical Pharmaceutical Company Inc.  Prior to that, he was global Senior VP of Operation & General Manager (Taicang) of Crown Bioscience Inc. and served as Board Chairman and General Manager of Taicang-Crownbio Biopharmaceutical Analysis, Inc. Dr. Qi has held several other notable roles including: Executive Director of Technical Operation, Client Services and Project Management of WuXi AppTec (Suzhou) Co., Ltd.; Research Fellow, Group Leader, Laboratory Technical Operations (LTO) Safety Assessment of Merck Research Laboratories (MRL); Sr. Clinical Project Manager/DBA of Becton, Dickinson and Company; Director of Department of Toxicology and Pharmacology, Beijing Institute for Drug Control of NMPA Beijing Branch.                                  

Dr. Qi received a Master of Business Administration in Pharmaceutical Management from Rutgers University in 2007, a Master of Science in Computer Science from Southeastern University in 1999, a Master of Public Health from Shanxi Medical University in 1991, and a Bachelor of Medicine (M.D. equivalent) from Shanxi Medical University in 1984.                                                                

 

Read Full Bio
Chengwei Fang

Chengwei Fang

CSO, SVP of Bioanalytical & BD, Frontage China
Chengwei Fang

Chengwei Fang

CSO, SVP of Bioanalytical & BD, Frontage China

Dr. Fang has over 20 years of experience in pharmaceutical and agrochemical R&D. Before joining Frontage, he worked as an Environmental Fate and Metabolism Researcher at BASF Agro Research (2000-2004). He then moved on and joined Merck Company (2004-2006) and AstraZeneca Pharmaceuticals LP (2006-2010) and engaged in both discovery and regulated bioanalysis research. He served as Executive Director, Head of DMPK and Regulated Bioanalysis Department at Pharmaron (2010-2014), and as Principal Investigator of Environmental Fate and Metabolism at Corteva Agriscience (2014-2020).

Dr. Fang has rich experience in the areas of ADME, PK/TK, and bioanalysis to support pharmaceutical R&D, environmental fate and metabolism of pesticides and regulatory sciences to support agrochemical registration.  He has extensive knowledge on GXP regulations from various authorities including FDA, NMPA, OECD and EPA. He has proven strengths in managing multiple projects and performing complex analytical tasks and has excellent track record on leading teams and delivering high-quality services to clients. Dr. Fang graduated from Delaware University in 1999 with a Ph.D. in Plant and Soil Science.

Read Full Bio
Min Wang

Min Wang

COO, VP of Clinical &Operation, Frontage China
Min Wang

Min Wang

COO, VP of Clinical &Operation, Frontage China

Min Wang has more than 10years of industrial experience. Before joined in Frontage, She had been worked as project director and team leader for project managers. The therapeutic areas she had been involved including oncology, endocrinology, cardiology, gastroenterology, rheumatology and immunology studies from phase I till phase III, as well as in Vitro Diagnostic trials. She has chaired many studies passed inspection by CFDI, before the product marked.

Min Wang graduated from North China Coal Medical University, and now is working towards master’s degree of EMBA. Min had been working in Southerncross healthcare group as assistant Nurse in England from 2008 till 2010.

Read Full Bio
Penny Wang

Penny Wang

VP of BD, Frontage China
Penny Wang

Penny Wang

VP of BD, Frontage China

Penny Wang has been deeply engaged in business development for more than 20 years and held various experience in different companies, including marketing, sales management, project management and corporate operations. She has accumulated rich experience in marketing strategy formulation, customer relationship establishment and operation, business negotiation and sales strategy development.

Penny Wang graduated from ShanghaiTech University,earned bachelor degree,and earned MBA from Massey University

Read Full Bio
Mankit

Mankit

SVP of Frontage China,General Manager of CMC China
Mankit

Mankit

SVP of Frontage China,General Manager of CMC China

Dr. Mankit Ho leads the Frontage CMC (Chemistry Manufacture & Control) Services in China, which include products development, analytical services, and manufacturing of clinical trial materials. Dr. Ho has more than 20 years pharmaceutical experience in pharmaceutical products development. Prior to joining Frontage, Dr. Ho held senior positions at Kashiv Pharma (Senior Vice President) and Teva Pharmaceuticals/Barr Laboratories (Director), where he led teams in successfully developed, filed, and approved for numerous generic (ANDA), 505(b)(2), new drug (NDA) products.

Dr. Ho earned a PhD degree in Analytical Chemistry from Iowa State University, followed by postdoctoral research at The University of Arizona. He received a BS degree in Chemistry from The Chinese University of HongKong.

Read Full Bio
Yinghua Du

Yinghua Du

Senior Vice President of China DMPK Services
Yinghua Du

Yinghua Du

Senior Vice President of China DMPK Services

Dr. Du has over 15 years of US industry experience in drug discovery and development, with a particular focus on biometabolism and bioanalytical (including GLP compliant, GCP clinical sample analysis). She has led and fully participated in two drug candidates for IND filings in the bioanalytical and DMPK areas, including the successful IND and NDA submissions for Sustiva (HIV drug), and the IND and clinical phase I and II DMPK studies for Pfizer’s anti-cancer drug Sutent-Sotan, and has deep expertise in mass spectrometry. Prior to joining Frontage, Dr. Du was the founder and CSO of Calibra, a technology company focused on clinical testing and clinical biomarker development and IVD kit manufacturing.
Dr. Du graduated from Brigham Young University, Provo, Utah, with a Ph.D in analytical chemistry (1991-1996). She has a patent (Alicia (Yinghua) Du, “Method of Neonatal Urine Screening for Organic Acid” U.S. Patent, US2010/ 0126254A1, May 27, 2010). 0126254A1, May 27, 2010, Mass Spectrometry of Organic Acids in Neonatal Urine) and more than 50 abstracts from journals and academic conferences. Contributed several chapters in two books on drug analysis and toxicology. He has taught several short courses on bioanalysis, especially at the China Mass Spectrometry Conference and at the ASMS Mass Spectrometry User Conference in the US. Dr. Du is one of the founding members of CBF (China Bioanalytical Forum) and has led and participated in the successful annual meetings in Beijing, Shanghai and Nanjing for several years.

Read Full Bio
Lian Chen

Lian Chen

VP of Frontage China Biological Analysis
Lian Chen

Lian Chen

VP of Frontage China Biological Analysis

Dr. Chen has been engaged in bioanalysis and DMPK research in the United States for more than 10 years, and has enriched  CRO experience of  laboratory operation, scientific management and business development, and is an expert in GLP related regulations. She has rich experience in the development and validation of small molecules, metabolites, preparation samples, biomarkers, peptides, antibody conjugated drugs and oligonucleotides by LC-MS. Dr. Chen has published more than 10 papers and reports in famous foreign journals.

Dr. Chen earned PhD degree in college of pharmacy from University of Illinois, received Bachelor degree in medicine from Wuhan University.

Read Full Bio
Yinling Li

Yinling Li

VP of Frontage China Biological Analysis
Yinling Li

Yinling Li

VP of Frontage China Biological Analysis

Dr. Li has been engaged in bioanalysis in the United States for more than 10 years, familiar with GLP and drug management regulatory. Dr. Li has enriched experience in bioanalysis especially in ADA/Nab method establish, validation and sample analysis. Dr. Li has a unique advantage in optimizing project management and implementing complex methods, and is recognized by clients for delivering high quality services within limited time. Before joining in Frontage, Dr. Li worked in QPS, Takeda, BioAgilytix, Amgen. During working, Dr. Li was responsible for Biologics analysis method establish, validation and sample analysis, biologics lab established, new technology development and team optimization.

Dr. Li earned PhD degree in physical chemistry from Peking University, received master degree in organic chemistry from Institute of Physical Chemistry Chinese Academy of Sciences.

Read Full Bio
Hemei Wang

Hemei Wang

VP & Deputy director of safety Evaluation Center,Frontage China
Hemei Wang

Hemei Wang

VP & Deputy director of safety Evaluation Center,Frontage China

Dr. Wang has been engaged in non-clinical safety evaluation of drugs for more than 20 years. He is familiar with GLP regulations at home and abroad and has rich experience in toxic pathology and toxicology. At present, he is also the vice chairman of the Committee of Toxic Pathology, Chinese Pharmaceutical Society, The Toxicology Committee of the Scientific Society, The Veterinary Pathology Branch of the Chinese Veterinary Medicine Association, the GLP examination expert and CDE New Drug evaluation expert of NMPA, the certified pathologist of the Chinese Veterinary Pathology Society, and the senior member of STP, ESTP and JSTP.

Dr. Wang has undertaken more than 10 national or military longitudinal research projects, published more than 50 papers, more than 80 conference abstracts at home and abroad, 6 monographs as chief translator, and 3 monographs as chief editor or co-editor. Dr. Wang has won two second prize of Military Science and Technology Progress award and one Science and Technology Progress Award of China Association of Traditional Chinese Medicine. In 2021, he was funded by Jiangsu Province “Entrepreneurship and Innovation Talents” and won the army individual Third-class merit award once.

Dr. Wang graduated from Tongji Medical College of Huazhong University of Science & Technology,earned PhD degree in Health Toxicology from Academy of Military Medical Sciences,and experienced post-doctoral research at Medical Center of Johannes Gutenberg-Universität Mainz, Germany.

Read Full Bio
June Xiao

June Xiao

Vice President of China QA
June Xiao

June Xiao

Vice President of China QA

Has in depth knowledge of quality&compliance in research and development and manufacturing process in the pharmaceutical healthcare industry.
She began her professional career as analytical chemist in the GMP manufacturing facilities of Wyeth and Organon in Ireland for over 12 years,assumed various positions in the quality control,technical validation departments with increasing responsibility as team leader and section leader.
She moved back to China in early 2006,joined Frontage in Shanghai during its starting phase as QA director, and later on move to V.P. position responsible for overall quality system in the China operation.
In early 2010,she joined Johnson&Johnson global pharma R&D QA organization as QA director supporting all global and regional non regulated,preclinical and GCLP projects in the region.

Read Full Bio
Liu Shi

Liu Shi

VP of Frontage China,Vice General Manager of Heyan
Liu Shi

Liu Shi

VP of Frontage China,Vice General Manager of Heyan

Mrs. Shi has accumulated rich experience in the early stage of drug development activity screening, focusing on the development and validation of various in vitro screening systems related to drug development targets such as GPCR, nuclear receptor, enzymology and high throughput screening.

Mrs. Shi graduated from Beijing Institute of genome research, Chinese Academy of Sciences.

Read Full Bio
Dong Yang

Dong Yang

VP of ACME
Dong Yang

Dong Yang

VP of ACME

Mr. Yang has over 20 years of experience in biomedical R&D and project management. From 2009, Mr. Yang responsible for ACME operation. Before joining Frontage, He held key positions at Sinopec, Shanghai Zeyuan and Shanghai Badi.

Mr. Yang received bachelor degree from Shanghai Jiao Tong University, master degree from Tsinghua University, and EDP degree from Fudan University.

Read Full Bio
en_USEnglish